Background:Hypertension is usually defined by the presence of a chronic elevation of systemic arterial pressure above a certain threshold value. However, increasing evidence indicates that the cardiovascular (CV) risk associated with elevation of blood pressure (BP) above approximately 115/75 mmHg increases in a log‐linear fashion. Materials and Methods:100 patients classified as having mild to moderate hypertension, 50 were assigned to the amlodipine group (Group-A) and the remaining 50 to the cilnidipine group (Group-B). Participants in Group-A received a daily dosage of 5 mg of Amlodipine, while those in Group-B were administered 10 mg of Cilnidipine daily, with both groups having been on their respective treatments for over six months. The selection of patients was conducted with careful adherence to established eligibility criteria, and various demographic, clinical, and biochemical parameters were recorded and subsequently analyzed for comparison. Using SPSS software. Results: In this study, the mean age of the subjects of Amlodipine group was 52.28 ±7.35 years and the mean age of the subjects of Cilnidipine group was 52.07 ±11.43 years. In Amlodipine group, there were 30 males and 20 females. In Cilnidipine group, there were 33 males and 17 females. The systolic BP of subjects in Amlodipine group and Cilnidipine group was 143.26±3.41 mm Hg and139.11±2.73 mm Hg, respectively. The diastolic BP of subjects in Amlodipine group and Cilnidipine group was 85.63±8.11 mm Hg and 81.41±5.70 mm Hg, respectively. The pulse rate of subjects in Amlodipine group and Cilnidipine group was 79.50±13.81 breathes/minute and 72.66±9.59 breathes/minute, respectively. Conclusion: Both Amlodipine and Cilnidipine are recognized as effective antihypertensive agents. However, the group receiving Cilnidipine exhibited a greater decrease in blood pressure compared to the group treated with Amlodipine.